Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of morinda officinalis oligose capsule in mild to moderate depressive disorder
ChiCTR1800014897Phase 4Completed
- Sponsor
- Peking University Sixth Hospital
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of morinda officinalis oligosaccharide in major depressive disorder (MDD) (3 arms), sponsored by Peking University Sixth Hospital. Primary endpoints: Response rate and remission rate, Relapse rate and/or time to relapse and 1 more. Started Apr 2014; status: completed.
02
Drugs
morinda officinalis oligosaccharide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1800014897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014897.